Status:
COMPLETED
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
Lead Sponsor:
AbbVie
Conditions:
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
Brief Summary
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections) and is the most common acute leukemia in adults. This study will...
Eligibility Criteria
Inclusion
- \- All participants who are administered venetoclax for treatment of AML.
Exclusion
- None
Key Trial Info
Start Date :
May 28 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2024
Estimated Enrollment :
424 Patients enrolled
Trial Details
Trial ID
NCT04813263
Start Date
May 28 2021
End Date
April 30 2024
Last Update
April 27 2025
Active Locations (281)
Enter a location and click search to find clinical trials sorted by distance.
1
Anjou Kousei Hospital /ID# 244213
Anjo-shi, Aichi-ken, Japan, 446-8602
2
Nagoya City West Medical Center /ID# 250844
Nagoya, Aichi-ken, Japan, 462-8508
3
Aichi Cancer Center Hospital /ID# 243785
Nagoya, Aichi-ken, Japan, 464-8681
4
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 242173
Nagoya, Aichi-ken, Japan, 466-8650